FLT3 and acute myeloid leukemia: To explore the factors influencing resistance of primary AML cells with D835 mutation in the tyrosine kinase domain (FLT3-ITD/D835) to tyrosine kinase inhibitors (TKIs), cap analysis gene expression technology was used to compare these cells to unmutated FLT3-ITD cells [54].